Impact of Psychological Screening on Routine Outpatient Care of Hematopoietic Cell Transplantation Survivors  by Hoodin, Flora et al.
Biol Blood Marrow Transplant 19 (2013) 1493e1497American Society for Blood
ASBMT
and Marrow TransplantationImpact of Psychological Screening on Routine Outpatient
Care of Hematopoietic Cell Transplantation Survivors
Flora Hoodin 1,2,*, Lili Zhao 3, Jillian Carey 2, John E. Levine 4, Carrie Kitko 4
1Department of Psychiatry, University of Michigan, Ann Arbor, Michigan
2Department of Psychology, Eastern Michigan University, Ypsilanti, Michigan
3Department of Biostatistics, University of Michigan, Ann Arbor, Michigan
4Division of Hematology Oncology, University of Michigan, Ann Arbor, MichiganArticle history:
Received 3 May 2013
Accepted 18 July 2013
Key Words:
Hematopoietic stem cell
transplantation
Depression
Screening
Psychological
Cancer survivorshipFinancial disclosure: See Acknowle
* Correspondence and reprint re
of Psychiatry, University of Michig
MCHC/Box 0295, Ann Arbor, MI 48
E-mail address: fhoodin@emich
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
Hematopoietic cell transplantation recipients are at high risk for psychological distress, with reported
prevalence rates as high as 40%. Although published guidelines advocate periodic routine screening, it is
unclear how screening affects management of psychological symptoms at routine post-HCT outpatient clinic
visits. We hypothesized that providers will be more likely to act on patients’ psychological symptoms if
a screening survey is completed and reviewed before a clinic visit. We used a brief, diagnostically focused
Patient Health Questionnaire (PHQ), to assess for depressive disorders, anxiety, substance abuse, and prob-
lems in occupational or interpersonal functioning (functional disruption). Adult HCT survivors were
randomized to complete the PHQ before meeting with their medical provider (n ¼ 50; experimental group) or
afterwards (n ¼ 51; control group). Providers used the experimental group PHQ results at their discretion
during the visits. Both providers and patients rated their satisfaction with management of psychological
concerns after the visit. The prevalence of clinically signiﬁcant depression (21%), anxiety (14%), or suicidal
ideation (8%) did not differ between the 2 groups. Patients in the experimental group were signiﬁcantly more
likely to have discussion of psychological symptoms than the control group (68% versus 49%, P ¼ .05). Medical
providers were signiﬁcantly more satisﬁed with the management of psychological issues for the experimental
group (P < .001). Patients with depression or anxiety were signiﬁcantly more likely to prefer the PHQ be used
at future visits (P ¼ .02 and P ¼ .001, respectively). These ﬁndings suggest an informative yet brief self-report
psychological screen can be easily integrated into routine care of hematopoietic cell transplantation survivors,
stimulates discussion of psychological symptoms, and improves provider satisfaction with psychological
symptom management. Future research will evaluate whether serial prospective administration improves
patient outcomes.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION The aim of the current study was to extend existing
Many adults cope well after hematopoietic stem cell
transplant (HCT). However, HCT elicits strong psychological
responses in a sizeable minority of patients, not all of them
with a history of pre-HCT psychopathology. The overall
prevalence of psychological difﬁculties during initial hospi-
talization is high (44%), and includes mood (14%), anxiety
(8%), and adjustment (23%) disorders [1]. In the long term,
HCT survivors remain at risk for emotional and/or cognitive
difﬁculties, as indicated by a psychological distress preva-
lence rate of 43% in survivors more than 3 years after HCT [2].
Because diagnosis, prognosis, and treatment processes
involved in HCT can be expected to elicit a certain amount
of normative distress, differentiating between normal
and abnormal emotional responses is difﬁcult. Without a
systematic approach to identifying psychological distress,
many oncologists frequently miss symptoms of depression
[3,4]. Thus, a reliable and valid assessment method is
required. However, to be easily integrated into hectic routine
of HCT outpatient clinics, assessments need to be time-
efﬁcient, impose a low burden to patients, and be easy for
providers to interpret.dgments on page 1497.
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by evaluating (1) whether using the brief, diagnostically
focused, mental-healtheoriented PHQ [7] in routine outpa-
tient ofﬁce visits of HCT patients is feasible and useful in
identifying depression, anxiety, and substance abuse; (2)
whether it affects how HCT providers address psychological
distress; and (3) whether it affects the satisfaction of patients
and physicians with the care provided during these visits.We
hypothesized that compared with treatment as usual,
patients in the experimental group who were PHQ screened
before their routine outpatient visit would be more likely to
discuss emotional issues with their physician, resulting in
greater satisfaction of patients and physicians with the care
provided.
PATIENTS AND METHODS
Participants
This study was reviewed and approved by the University of Michigan
institutional review board. Patients were enrolled during standard sched-
uled post-HCT clinic visits in the University of Michigan Blood and Marrow
Transplant Clinic (August 2010 through February 2011). Inclusion criteria
included age  18 years, status 5 years after autologous or allogeneic HCT,
mental competence to provide informed consent, and ability to read and
speak English.
Procedure
The study was cross-sectional in design, and no patient participated
more than once. Upon completion of the informed consent, patients were
randomly assigned to complete the PHQ depression, anxiety, and substance
abuse modules before meeting with their medical provider (n ¼ 50;
experimental group) or afterwards (n ¼ 51; control group). All patients
Transplantation.
Table 1
Characteristics of the 101 Study Participants
Characteristic Mean  SD,
or n (%)
Range
Age, yr 51.06  13.77 18 to 70
Time from HCT to study, d 481.51  492.70 20 to 1801
Education, yr 14.49  2.75 10 to 24
Gender*, male 52 (51%)
Ethnicity*
White 95 (95%)
Black 4 (4%)
Other 2 (2%)
Married/partnered 69 (68%)
Income, annual
>$100,000 13 (13%)
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their physician, and afterwards they completed a postvisit questionnaire
regarding treatment decisions and satisfaction with the visit.
The 10 participating HCT physicians treated patients in both groups.
Physicians were given access to the experimental group’s PHQ scores to use
at their discretion during the visits. Physicians provided treatment as usual
to patients in the control group without access to PHQ data and without
being informed in advance of the visit that control patients were partici-
pating in the study. However, after control group visits, research assistants
immediately informed providers if patients had checked any response
other than “not at all,” in response to the PHQ item that assesses for
suicidal ideation. Physicians then responded as needed to that information.
After each visit, irrespective of group, providers completed a checklist
of psychological interventions initiated or continued at that visit, and
they rated their satisfaction with the visit and with the management of
psychological concerns.>$50,000 29 (29%)
>$25,000 25 (25%)
$25,000 15 (15%)
Prefer not to say 18 (18%)
Indication for HCT
Acute leukemia/MDS 49 (48%)
Non-Hodgkin lymphoma 23 (23%)
Multiple myeloma 12 (12%)
Other 17 (17%)
Type of HCT
Autologous 18 (18%)
Related donor 41 (41%)
Unrelated donor 42 (42%)
Acute GVHDy 42 (51%)y
Chronic GVHDy 44 (53%)y
Pre-HCT risk of relapse
(CIBMTR criteria)
Low 40 (40%)
Intermediate 44 (44%)
High 17 (17%)
Full-intensity conditioning 52 (51%)
Steroids use before study participation 32 (32%)
Steroid dose at study participationz,
mg/kg
.32  .31 .01 to 1.08
Relapsed before study participation 6 (6%)
Time from relapse to study, d 310.33  415.5 2 to 112
Karnofsky performance scale 81.98  8.83 70 to 100
HCT indicates hematopoietic cell transplantation; SD, standard deviation;
MDS, myelodysplastic syndrome; GVHD, graft-versus-host disease; CIBMTR,
Center for International Blood and Marrow Transplant Research.
* n ¼ 100.
y Percent of the 83 allogeneic graft recipients.
z Medrol dose equivalent.Measures
Medical variables were extracted from the medical database. Demo-
graphic information and history of prior mental health difﬁculties and
history of mental health treatment (behavioral and/or psychopharmaco-
logical) were assessed by patient report in a brief survey consisting of 28
items that was designed for this study. The timing of the diagnoses of mood
disorder (major depressive disorder, bipolar disorder, dysthymia) and
anxiety (generalized anxiety disorder, phobias, obsessive-compulsive
disorder, post-traumatic stress disorder, panic disorder) was individually
assessed by patients choosing 1 of 3 possible responses for each diagnosis:
(1) before HCT, (2) during or after HCT, or (3) never diagnosed with the
condition.
PHQ
The PHQ, which has been validated as a diagnostic screening instrument
for mood disorders, anxiety disorders, alcohol abuse disorders and other
psychopathology [7], was the primary questionnaire in this study. The PHQ
has high sensitivity and speciﬁcity for detecting generalized anxiety
disorder [8] and substance abuse [7,9], as well as making criteria-based
diagnoses of depressive disorders and indicating depression severity [10].
The PHQ modules used in this study were the 9-item depression
screener (PHQ-9; clinically signiﬁcant depression equates to a score10), 2-
item anxiety screener (GAD-2; clinically signiﬁcant anxiety equates to
a score 3), and 6-item alcohol abuse screener, which was only completed
in full if the lead question is answered in the afﬁrmative. In addition, we
used a 1-question screen that assessed if any emotional difﬁculties were
affecting occupational and/or interpersonal functioning, scored on a 4-point
scale from “not at all” to “extremely difﬁcult.” Endorsement of anything
other than “not at all” is referred to in this study as “functional disruption.”
With the permission of the PHQ authors, we created and deployed parallel
forms of the alcohol abuse screener to screen for recreational drug use (6
items) and prescription medication abuse (6 items). Thus the PHQ modules
consisted of a minimum of 15 questions that every participant answered,
and an additional 15 that were only answered if the participant admitted to
using alcohol (5 items), recreation drugs (5 items), or overusing prescription
medications (5 items). Completing all items on the questionnaire
(Supplementary Figure l) took approximately 2 minutes.
Postvisit patient satisfaction questionnaire
Patients completed a postvisit satisfaction questionnaire
(Supplementary Figure 2) that assessed (1) whether the visit included
discussion of mental, emotional, or behavioral issues (“yes” or “no”), (2) if
interventions in the form of psychopharmacological medication manage-
ment or referral tomental health providers occurred (“yes” or “no”), (3) their
attitudes toward using the PHQ in future (“always,” “sometimes,” or
“never”), and (4) their satisfaction with the visit. Patient visit satisfaction
was broken down into 3 categories: (1) overall, (2) the way mental health or
emotional issues were addressed, and (3) the provider’s concern for the
patient as “a whole person” and was rated on a 7-point scale Likert scale
from “not at all satisﬁed” to “very satisﬁed.”
Postvisit provider report
Providers completed a postvisit survey (Supplementary Figure 3) that
documented (1) whether mental health and emotional issues were dis-
cussed during the visit, (2) if interventions in the form of referral to mental
health providers or psychopharmacological medication management
occurred, (3) whether the information provided by the PHQ inﬂuenced
intervention for that visit, and (4) their satisfactionwith the visit overall and
with the degree to which psychosocial issues were addressed. The 2 satis-
faction ratings were on a 7-point scale Likert scale from “not at all satisﬁed”
to “very satisﬁed.”Statistical Analysis
SPSS Version 19 (SPSS Inc. Chicago, IL) was used for statistical analysis.
Standard descriptive statistics (frequency, means, standard deviation, and
range) were used to summarize the demographic, medical, and psycho-
logical variables and associations between variables were assessed by
Pearson correlation coefﬁcient for continuous variables and Spearman’s r
for ordinal variables. The 2-sample t-test was used to compare the experi-
mental and control groups on continuous measures of psychopathology and
satisfaction, and Pearson’s chi-square tests were used to compare groups on
the dichotomous principal outcome variables of discussion of mental health
issues, referral, and psychopharmacological prescription. Multiple linear
regression (for continuous outcomes) or logistic regression (for dichoto-
mous outcomes) were used to assess associations among the principal
outcome variables and other variables of interest.
RESULTS
Participants
Participants were 101 HCT survivors (83 allogeneic and 18
autologous graft recipients) with a median age of 53 years
(range, 18 to 70), who were a median of 9.5 months (range,
20 days to 4.99 years) post-HCT. The demographic and
medical characteristics are listed in Table 1. The experimental
and control groups did not differ signiﬁcantly in self-
reported past psychopathology. For the entire cohort, the
prevalence of self-reported mood disorder diagnoses was
Table 2
Self-Reported Incidence of Psychological Disorders before and after HCT
Disorder Before HCT After HCT Total
Mood disorders 8 (8%) 6 (6%) 14 (14%)
Mood 1 disorder* 7 (7%) 6 (6%) 13 (13%)
Depression 5 (5%) 6 (6%) 11 (11%)
Bipolar 2 (2%) 0 (0%) 2 (2%)
Dysthymia 1 (1%) 0 (0%) 1 (1%)
Anxiety 22 (22%) 18 (18%) 40 (40%)
Anxiety 1 disordery 19 (19%) 12 (12%) 31 (31%)
Generalized anxiety disorder 17 (17%) 10 (10%) 27 (27%)
Phobias 0 (0%) 0 (0%) 0 (0%)
Obsessive compulsive disorder 1 (1%) 2 (2%) 3 (3%)
Post-traumatic stress disorder 2 (2%) 3 (3%) 5 (5%)
Panic 2 (2%) 3 (3%) 5 (5%)
Substance abuse
Alcohol abuse 3 (3%) 0 (0%) 3 (3%)
Recreational drug abuse 2 (2%) 0 (0%) 2 (2%)
Medication abuse 1 (1%) 0 (0%) 1 (1%)
Axis II diagnosis 3 (3%) 2 (2%) 5 (5%)
Adjustment and otherz disorders 6 (6%) 14 (14%) 20 (20%)
Data are presented as n (%).
* More than 1 mood disorder.
y More than 1 anxiety disorder.
z Other includes attention deﬁcit disorder, body dysmorphic disorder,
interpersonal problems, sexual difﬁculties, death in family, grief, little
patience when in pain, and memory and cognitive dysfunction.
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and the prevalence of self-reported anxiety diagnoses was
40% (22% and 18% diagnosed before and after HCT, respec-
tively). The prevalence of self-reported history of substance
abuse diagnoses was 6% (Table 2). The proportion of patients
who recalled at least some need for mental health services
versus no need increased from 30% before HCT to 53% after
HCT (odds ratio [OR] 8.67; 95% conﬁdence interval [CI], 2.62
to 28.6; P < .001) (Figure 1).Current Psychopathology as Indicated by the PHQ
There were no statistically signiﬁcant differences
between the experimental and control groups in currentFigure 1. Perceived need for mental health assistance increased from before to
after HCT (P < .001).psychopathology according to the PHQ modules. However,
patients reported a higher incidence of depression (21%
versus 8%, P ¼ .001) and a lower incidence of anxiety (14%
versus 22%, P ¼ .01) but no statistically signiﬁcant change in
incidence of substance abuse, according to the post-HCT PHQ
diagnostic criteria, when compared with their recall of being
professionally diagnosed before HCT (Figure 2). Notably, 12%
of the study sample met PHQ criteria for more than 1 form of
psychopathology. Education level was unrelated to current
psychopathology or mental health diagnosis before HCT.
However, patients with less educationwere more likely to be
professionally diagnosed with a mental health disorder after
HCT (Spearman’s r ¼ .26, P ¼ .009).
Suicidal ideationwas surprisingly common. Eight percent
of all participants (4 patients in each arm) reported suicidal
thoughts for at least several days in the most recent 2 weeks.
Suicidal ideationwas positively correlatedwith the sum of all
other depressive symptoms (Spearman’s r ¼ .33, P < .001),
anxiety (Spearman’s r ¼ .23, P ¼ .02), and longer time since
transplantation (Spearman’s r ¼ .22, P ¼ .03), but negatively
correlated with age (Spearman’s r ¼ .21, P ¼ .04). Thus,
suicidal ideation was more likely in younger patients, those
with more depressive symptoms, and those further out from
HCT. Pre-HCT risk of relapse was not associated with suicidal
ideation. Suicidal ideationwas reported by 1 (out of 6, 16%) of
the patients who had relapsed after HCT but before study
participation. These small numbers preclude any formal
statistical analysis.
Psychological Intervention
In support of our hypothesis, patients in the experimental
arm were signiﬁcantly more likely to have discussion of
psychological symptoms than the control group (68% versus
49%, P ¼ .05). Univariate analyses indicated multiple demo-
graphic variables (gender, age, and years of education) and
medical variables (post-HCT relapse, days after HCT, dichot-
omized as <180 days or  181 days) did not impact the
likelihood of discussion. When these variables were
controlled for in a multiple logistic regression, there was still
a trend toward more discussion in the experimental group
(P ¼ .10). However, the 2 groups did not differ in rates of
referral to mental health providers (12% versus 10%, for the
experimental and control groups, respectively; P ¼ .49) or
prescription of psychotropic medication (14% in both the
experimental and control groups; P ¼ .60). As expected,
patients in either group who discussed “mental, emotional,
or behavioral problems” during their clinic visit were more
likely to be referred tomental health services (OR¼ 8.16; 95%
CI, 1.0 to 66.5; P ¼ .05) and prescribed psychotropic drugs
(OR ¼ 4.98; 95% CI, 1.1 to 23.6; P ¼ .03). The impact of
discussion on intervention (referrals or prescription) was not
signiﬁcantly affected when relevant demographic variables
(gender, age, and years of education) and medical variables
(post-HCT relapse, and days after HCT, dichotomized as
<180 days or >181 days) were controlled for in a multiple
logistic regression model.
Provider and Patient Perspectives
Patient satisfaction was skewed to the high end of the
rating scale and did not differ between groups. Patients with
clinically signiﬁcant depression or anxiety based on the PHQ,
regardless of study arm, were signiﬁcantly more likely to
wish that the questionnaire would be used at future outpa-
tient visits (depression: OR ¼ 3.88; 95% CI, 1.27 to 11.9; P ¼
.02; anxiety: OR ¼ 17.6; 95% CI, 2.18 to 142.3; P ¼ .001).
Figure 2. Percent of patients with clinically signiﬁcant functional disruption, depression, anxiety and substance abuse, as self-reported before HCT and as indicated by
PHQ at time of study participation.
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before the visit were signiﬁcantly more satisﬁed with their
patient management when compared with the control
group. The mean satisfaction of providers for the experi-
mental group was higher both for management of psycho-
logical problems (6.11 versus 5.56, P < .001) and for the visit
as a whole (5.89 versus 4.66, respectively; P ¼ .005).
Providers reported that information provided by the PHQ
inﬂuenced their psychological management for 48% of the
patients in the experimental group.
DISCUSSION
This study’s novel design, comparing effects of screening
versus treatment as usual without screening in routine
outpatient care of HCT survivors, addresses “the paucity of
clinical trials focused on screening and preventive practices”
noted by Rizzo [11] regarding the psychological status of HCT
survivors. By focusing on the screening process itself in
routine outpatient follow-up care, our study demonstrates
that when presented with informative psychological
screening data, HCT physicians were more likely to discuss
patients’ mental health concerns and demonstrated greater
satisfaction with the care provided to those patients. In
addition, patients who endorsed anxiety or depression
wished that the PHQ would be used in future visits.
For physicians, the act of acknowledging and reviewing
the PHQ results with the patient appeared to function as an
intervention, whether or not new referrals or psycho-
pharmaceutical interventions were viewed as needed at the
time. The absence of difference in terms of intervention
between the 2 groups could be because the physicians in this
study were already quite adept at detecting psychological
issues requiring clinical attention. Alternatively, use of the
PHQ in the experimental group may have sensitized physi-
cians to mental health concerns in the control group. Fromthe perspective of patients with depression or anxiety, dis-
cussing the PHQ results with their physicians was viewed as
beneﬁcial, based on their desire to continue use of the PHQ.
Although we did not investigate this directly, we surmise the
discussions of psychological issues might serve also to
strengthen the therapeutic alliance between physician and
patient who often work together for months or years.
Prevalence rates in our sample of clinically signiﬁcant
depression (21%) and anxiety (14%), as indicated by the brief
PHQ screening instrument, are consistent with rates re-
ported in the literature of patients 1 to 2 years after trans-
plantation [12,13].
The prevalence rate of suicidal ideation in our sample, not
commonly reported in the HCT literature, was alarming at
8%, although the conﬁdence interval is quite wide and
overlaps with the much lower 12-month prevalence rate of
2.8% to 3.3% in a large, nationally representative sample in
the United States [14]. Furthermore, it is possible that study
patients experiencing suicidal ideation may be more likely to
choose to participate in psychological screening studies,
which would skew our ﬁndings. Nonetheless, the brief
screening instrument used in this study, the PHQ-9, which
has been validated for use with cancer outpatients [15,16]
and HCT patients [17], facilitated provider detection of
suicidal thoughts. This ﬁnding suggests the PHQ could be
used regardless of specialty clinic setting, to assess all HCT
survivors, both short-term and long-term. More investiga-
tion is warranted to better quantify the degree of psycho-
logical distress during the post-HCT recovery period.
Although the majority of transplant centers conduct
psychosocial assessments of their patients before HCT, our
study suggests that ongoing clinical assessment is needed, as
not all patients experiencing distress after HCT can be
identiﬁed on the basis of their distress before HCT. In our
study, a modiﬁed PHQ demonstrated utility for facilitating
F. Hoodin et al. / Biol Blood Marrow Transplant 19 (2013) 1493e1497 1497discussion of emotional wellbeing and resulted in higher
physician satisfaction with the care provided during routine
outpatient HCT follow-up visits. Furthermore, assessment by
the modiﬁed PHQ was feasible in the outpatient setting. As
a future direction, we propose to evaluate patients serially,
which should allow for timely identiﬁcation of emotional
distress and promote discussion between patients and
providers. We expect serial PHQ assessments would also
provide physicians with an objective method to evaluate
response to any given intervention. In the meantime, our
study results support the use of the modiﬁed PHQ as a useful
psychological assessment tool for outpatient HCT recipients,
particularly when the provider reviews the results before
meeting with the patient.ACKNOWLEDGMENTS
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